Heart Medications

Why the first 60 minutes after a heart attack can make all the difference

The first hour after a heart attack can mean the difference between survival and lasting damage; doctors explain what to do in the Golden Hour

Shingles vaccine may reduce heart disease risk by 23%, says report

Getting vaccinated against shingles could lower the chances of a cardiovascular event, such as stroke or heart failure, by 23 per cent, according to a study. Protective effects of the vaccine for shingles -- a viral infection that causes painful rashes -- could last for up to eight years and be stronger among men and people aged under 60. Researchers, led by those from the Kyung Hee University's college of medicine, South Korea, looked at over 12 lakh residents of the country, aged at least 50. Data on shingles vaccination status was collected from 2012 onwards and analysed together with cardiovascular health and lifestyle. Published in the European Heart Journal, the study is "one of the largest and most comprehensive" to provide evidence at a population level, allowing the team to look at the link between vaccination and 18 different types of cardiovascular disease. "There are several reasons why the shingles vaccine may help reduce heart disease. A shingles infection can cause .

Ban on popular heartburn drug Ranitidine deferred amid cancer concerns

Despite NDMA-related cancer concerns and global withdrawals, Indian drug regulators have opted not to suspend Ranitidine, pending further safety review and investigation by a larger expert committee

Cardiac stents to cost 2% more as regulator allows prices to be raised

National Pharmaceutical Pricing Authority allows manufacturers to make adjustment for inflation

On fitness track: More women prioritise physical health, shows data

Data from healthcare platforms reveals surge in cardiac consultations, preventive checkups

Essential medicines set for a highest ever price rise of 12% this year

Prices of 900 formulations are expected to increase to reflect annual change in WPI

Glenmark pharma launches generic version of Novartis' heart failure drug

Opens floodgates for more generic launches; 40 new brands expected

Abbott gets DCGI nod for once-a-day heart failure, angina treatment drug

Global healthcare firm Abbott on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks, Abbott said in a statement. This formulation will be more convenient for patients, which will help facilitate treatment adherence with the aim to improve health outcomes, it added. The formulation has been developed at Abbott's innovation & development (I&D) centre in Mumbai, the statement said. "Adherence to therapy is a critical factor to maximize the overall health of people with chronic heart failure or chronic stable angina. We have used the best technology and science to develop this new dosage formulation," Abbott Regional Medical Director Balagopal Nair said. The convenient once-a-day formulation will help improve overall ...

Finishing a marathon can spruce up arteries, make them flexible: Study

The study finds that training for and finishing a marathon can spruce up arteries, leaving them more flexible, healthy and biologically younger than before, even if runners are older or slow

Popular heart drugs tainted with carcinogens face a wave of lawsuits

Millions of Americans have taken the drugs, which are at the center of a widening recall being overseen by the USFDA